Double Bond Pharmaceutical

Double Bond Pharmaceutical (DBP) is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company's both front-line products were recently granted Orphan Drug Designation status by European Medicines Agency (EMA): in June 2015 for its first product, SA-033, for treatment of hepatoblastoma (liver cancer), and in July 2016 for its second product, Temodex, for treatment of brain tumours. DBP has acquired Temodex from Belarus in October 2015 and the drug is already registered and used as a first-line treatment of glioblastoma in Belarus since 2014.